References

Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review

10.1001/jamacardio.2021.2241 · ExternalCitation · doi-reference

Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis

10.1001/jamaoncol.2024.3065 · ExternalCitation · doi-reference

Immune checkpoint inhibitor-associated cardiovascular toxic effects: international cardio-oncology society position statement

10.1001/jamaoncol.2025.4543 · ExternalCitation · doi-reference

Cardiovascular adverse events associated with immune checkpoint inhibitors: a retrospective multicenter cohort study

10.1002/cam4.7233 · ExternalCitation · doi-reference

Immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: a case report

10.1002/ccr3.8968 · ExternalCitation · doi-reference

Immune checkpoint inhibitor-related myocarditis: a single center observational registry

10.1002/clc.70154 · ExternalCitation · doi-reference

Subtle-but-smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits

10.1002/ehf2.13915 · ExternalCitation · doi-reference

Right ventricular and atrial strain in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy

10.1002/ehf2.14094 · ExternalCitation · doi-reference

Previous cardiovascular injury is a prerequisite for immune checkpoint inhibitor-associated lethal myocarditis in mice

10.1002/ehf2.14614 · ExternalCitation · doi-reference

Immune checkpoint inhibitors and cardiovascular adverse events

10.1002/ehf2.15281 · ExternalCitation · doi-reference

Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the cardio-oncology study group of the heart failure association and the cardio-oncology council of the European Society of Cardiology

10.1002/ejhf.2017 · ExternalCitation · doi-reference

Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the heart failure association (HFA) of the ESC and the ESC council of cardio-oncology

10.1002/ejhf.3340 · ExternalCitation · doi-reference

Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis

10.1002/ijc.34169 · ExternalCitation · doi-reference

Immune checkpoint inhibitor (ICI)-related cardiotoxicity

10.1007/978-3-030-79308-1_15 · ExternalCitation · doi-reference

New concepts in cardio-oncology

10.1007/978-3-031-33602-7_12 · ExternalCitation · doi-reference

The predictive value of high sensitivity troponin measurements in patients treated with immune checkpoint inhibitors

10.1007/s00392-022-02118-8 · ExternalCitation · doi-reference

Adverse myocardial and vascular side effects of immune checkpoint inhibitors: a prospective multimodal cardiovascular assessment

10.1007/s00392-024-02462-x · ExternalCitation · doi-reference

Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin

10.1007/s00395-024-01046-0 · ExternalCitation · doi-reference

Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors

10.1007/s00395-024-01068-8 · ExternalCitation · doi-reference

Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy

10.1007/s00395-024-01070-0 · ExternalCitation · doi-reference

Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series

10.1007/s00415-023-12134-x · ExternalCitation · doi-reference

Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea

10.1007/s00432-022-04516-x · ExternalCitation · doi-reference

Vasculitis associated with immune checkpoint inhibitors-a systematic review

10.1007/s10067-018-4177-0 · ExternalCitation · doi-reference

Cytokine profiling of patients with immune checkpoint inhibitor-associated myocarditis: a pilot study

10.1007/s11033-025-11095-w · ExternalCitation · doi-reference

Immune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management

10.1007/s11239-025-03146-7 · ExternalCitation · doi-reference

Role of biomarkers in the management of immune-checkpoint inhibitor-related myocarditis

10.1007/s11886-023-01915-5 · ExternalCitation · doi-reference

New insights into mechanisms of immune checkpoint inhibitor-induced cardiovascular toxicity

10.1007/s11912-020-00925-8 · ExternalCitation · doi-reference

Immune-Related adverse events (irAEs): diagnosis, management, and clinical pearls

10.1007/s11912-020-0897-9 · ExternalCitation · doi-reference

Cardiovascular toxicities of CAR T-cell therapy

10.1007/s11912-021-01068-0 · ExternalCitation · doi-reference

Cardiotoxicity of immune checkpoint Inhibitors

10.1007/s11912-021-01070-6 · ExternalCitation · doi-reference

Interventional strategies in cancer-induced cardiovascular disease

10.1007/s11912-021-01113-y · ExternalCitation · doi-reference

Cardiovascular effects of immune checkpoint inhibitors: more than just myocarditis

10.1007/s11912-023-01411-7 · ExternalCitation · doi-reference

Risk factors for immune checkpoint inhibitor-mediated cardiovascular toxicities

10.1007/s11912-023-01414-4 · ExternalCitation · doi-reference

Cardiotoxicity of immune checkpoint inhibitors

10.1007/s11936-019-0731-6 · ExternalCitation · doi-reference

Cardiotoxicity of contemporary anticancer immunotherapy

10.1007/s11936-020-00867-1 · ExternalCitation · doi-reference

Immunotherapy-Associated atherosclerosis: a comprehensive review of recent findings and implications for future research

10.1007/s11936-023-01024-0 · ExternalCitation · doi-reference

Role of echocardiography in patients treated with immune checkpoints inhibitors

10.1007/s12574-023-00621-z · ExternalCitation · doi-reference

Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors

10.1007/s12672-024-01416-z · ExternalCitation · doi-reference

Cardiotoxicity of immune therapy

10.1016/j.ccl.2019.07.008 · ExternalCitation · doi-reference

Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis

10.1016/j.celrep.2022.111611 · ExternalCitation · doi-reference

Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors

10.1016/j.ctrv.2021.102282 · ExternalCitation · doi-reference

Cardiotoxicities associated with immune checkpoint inhibitors

10.1016/j.currproblcancer.2018.07.002 · ExternalCitation · doi-reference

Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: influence of comorbidities and clinical outcomes

10.1016/j.ejca.2025.115404 · ExternalCitation · doi-reference

Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy

10.1016/j.esmoop.2021.100216 · ExternalCitation · doi-reference

Atherosclerotic cardiovascular events in cancer patients treated with immune checkpoint inhibitors: a retrospective cohort study

10.1016/j.hlc.2023.10.008 · ExternalCitation · doi-reference

Cardiotoxicity in cancer immune-checkpoint therapy: mechanisms, clinical evidence, and management strategies

10.1016/j.ijcard.2021.09.041 · ExternalCitation · doi-reference

Cardiac magnetic resonance imaging in patients with suspected myocarditis from immune checkpoint inhibitor therapy - A real-world observational study

10.1016/j.ijcha.2024.101581 · ExternalCitation · doi-reference

Insight of immune checkpoint inhibitor related myocarditis

10.1016/j.intimp.2024.113559 · ExternalCitation · doi-reference

Elevations of cardiac troponin in patients receiving immune checkpoint inhibitors: data from a prospective study

10.1016/j.jacadv.2024.101375 · ExternalCitation · doi-reference

Prognostic value of biomarkers in cancer patients treated with immune checkpoint inhibitor therapy

10.1016/j.jacadv.2025.102022 · ExternalCitation · doi-reference

Myocarditis in patients treated with immune checkpoint inhibitors

10.1016/j.jacc.2018.02.037 · ExternalCitation · doi-reference

The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: cardioOncology primer

10.1016/j.jaccao.2020.11.012 · ExternalCitation · doi-reference

Longitudinal strain and troponin I elevation in patients undergoing immune checkpoint inhibitor therapy

10.1016/j.jaccao.2022.10.007 · ExternalCitation · doi-reference

Incidence of MACE in patients treated with CAR-T cell therapy: a prospective study

10.1016/j.jaccao.2023.07.009 · ExternalCitation · doi-reference

Immune checkpoint inhibitor myocarditis and left ventricular systolic dysfunction

10.1016/j.jaccao.2025.01.020 · ExternalCitation · doi-reference

Cardiac troponin screening and clinical outcomes in patients receiving immunotherapy

10.1016/j.jaccao.2025.06.009 · ExternalCitation · doi-reference

PD-L1 in ICI myocarditis: when the immune brake fails

10.1016/j.jaccao.2026.03.003 · ExternalCitation · doi-reference

CAR-T Therapy in lymphoma patients with coexisting cardiomyopathy or cardiac lymphomatous involvement

10.1016/j.jaccas.2023.101840 · ExternalCitation · doi-reference

Successful use of ruxolitinib for steroid-refractory immune checkpoint inhibitor-associated myocarditis

10.1016/j.jaccas.2025.105543 · ExternalCitation · doi-reference

Immune checkpoint inhibitor cardiotoxicity: breaking barriers in the cardiovascular immune landscape

10.1016/j.yjmcc.2021.07.006 · ExternalCitation · doi-reference

Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart

10.1038/s41568-024-00715-5 · ExternalCitation · doi-reference

Cardiotoxicity of T cell immunotherapies

10.1038/s41569-026-01265-z · ExternalCitation · doi-reference

How can we manage the cardiac toxicity of immune checkpoint inhibitors?

10.1080/14740338.2021.1906860 · ExternalCitation · doi-reference

Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicity

10.1080/1750743x.2024.2385286 · ExternalCitation · doi-reference

Immune checkpoint inhibitor-induced myocarditis is dependent on CD8 T cell-derived TNF and TNFR2 signaling

10.1084/jem.20251717 · ExternalCitation · doi-reference

Cardiovascular toxicities associated with immune checkpoint inhibitors

10.1093/cvr/cvz026 · ExternalCitation · doi-reference

Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with Abatacept and ruxolitinib: a case report

10.1093/ehjcr/ytaf019 · ExternalCitation · doi-reference

Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients

10.1093/eurheartj/ehad117 · ExternalCitation · doi-reference

Immune checkpoint inhibitor-associated myocarditis: a novel risk score

10.1093/eurheartj/ehaf315 · ExternalCitation · doi-reference

The predictive value of serial troponin measurements in patients treated with immune checkpoint inhibitors

10.1093/oncolo/oyaf147 · ExternalCitation · doi-reference

Immune checkpoint inhibitor-related myocarditis: a comprehensive analysis of clinical manifestations and prognostic factors

10.1093/oncolo/oyaf285 · ExternalCitation · doi-reference

Immune checkpoint inhibitors-induced large vessel vasculitis: clinical characteristics and management from a European multicentre study

10.1093/rheumatology/keaf172 · ExternalCitation · doi-reference

Nivolumab- and ipilimumab-induced myositis, myasthenia gravis, and myocarditis in a patient with metastatic melanoma

10.1097/cad.0000000000001727 · ExternalCitation · doi-reference

Pembrolizumab-Induced acral vasculitis

10.1097/cji.0000000000000457 · ExternalCitation · doi-reference

Cardiovascular risk profile of nivolumab anti-cancer therapy: a review of current literature

10.1097/coc.0000000000001166 · ExternalCitation · doi-reference

Epicardial metastases causing coronary artery compression and myocardial infarction on [ 18 F]FDG PET-CT

10.1097/rlu.0000000000005819 · ExternalCitation · doi-reference

Cardiovascular immune-related adverse events: evaluation, diagnosis and management

10.1111/ajco.13326 · ExternalCitation · doi-reference

Cardiac adverse events in patients receiving immune checkpoint inhibitors in the adjuvant setting: an FDA pooled analysis

10.1111/anec.70087 · ExternalCitation · doi-reference

Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment

10.1111/bph.15984 · ExternalCitation · doi-reference

Multimodality imaging and immune-related adverse events during immune checkpoint inhibitors treatment: where do we stand?

10.1111/echo.70115 · ExternalCitation · doi-reference

Applications, challenges and future directions of artificial intelligence in cardio-oncology

10.1111/eci.14370 · ExternalCitation · doi-reference

The cardiotoxic effects of CAR-T cell therapy: an updated systematic review and meta-analysis

10.1111/ejh.14289 · ExternalCitation · doi-reference

Mediators and mechanisms of immune checkpoint inhibitor-associated myocarditis: insights from mouse and human

10.1111/imr.13240 · ExternalCitation · doi-reference

Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis

10.1126/scitranslmed.abo1981 · ExternalCitation · doi-reference

Concomitant myopericarditis and takotsubo syndrome following immune checkpoint inhibitor therapy

10.1136/bcr-2020-235265 · ExternalCitation · doi-reference

Checkpoint inhibitor myocarditis with preceding immunosuppression and tolerance of sequential anthracycline therapy

10.1136/bcr-2023-257357 · ExternalCitation · doi-reference

Cardiovascular toxicity of immune therapies for cancer

10.1136/bmj-2023-075859 · ExternalCitation · doi-reference

Cardiotoxicities of novel cancer immunotherapies

10.1136/heartjnl-2020-318083 · ExternalCitation · doi-reference

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis

10.1136/jitc-2020-001887 · ExternalCitation · doi-reference

Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem

10.1136/jitc-2021-002916 · ExternalCitation · doi-reference

(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis

10.1136/jitc-2021-003594 · ExternalCitation · doi-reference

New perspectives in cancer immunotherapy: targeting IL-6 cytokine family

10.1136/jitc-2023-007530 · ExternalCitation · doi-reference

Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events

10.1136/jitc-2024-010568 · ExternalCitation · doi-reference

Identification of features and differences in PD-1 inhibitor-associated myocarditis and acute myocardial infarction using proteomic analysis: a clinical and preclinical study

10.1139/bcb-2025-0170 · ExternalCitation · doi-reference

[Clinical features of myasthenia Gravis as an immune-related adverse event]

10.11477/mf.1416202554 · ExternalCitation · doi-reference

Cardiac MRI features and prognostic value in immune checkpoint inhibitor-induced myocarditis

10.1148/radiol.211765 · ExternalCitation · doi-reference

Myocarditis mimicking takotsubo cardiomyopathy with first dose of neoadjuvant nivolumab-relatlimab

10.1155/crom/1443004 · ExternalCitation · doi-reference

Concurrent nivolumab-induced myocarditis and myasthenia Gravis: a case report

10.1155/crom/9486566 · ExternalCitation · doi-reference

Statin and immune-related cardiovascular events in lung cancer patients receiving immune checkpoint inhibitors

10.1159/000546204 · ExternalCitation · doi-reference

Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis

10.1161/circulationaha.123.062405 · ExternalCitation · doi-reference

Cardio-oncology: a new clinical frontier and novel platform for cardiovascular investigation

10.1161/circulationaha.124.065473 · ExternalCitation · doi-reference

Immune checkpoint inhibitors and cardiotoxicity: a comparative meta-analysis of observational studies and randomized controlled trials

10.1161/jaha.123.032620 · ExternalCitation · doi-reference

Cardiovascular toxicities associated with novel cellular immune therapies

10.1182/bloodadvances.2024013849 · ExternalCitation · doi-reference

Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database

10.1186/s12885-025-14668-x · ExternalCitation · doi-reference

Machine learning and multi-omics integration: advancing cardiovascular translational research and clinical practice

10.1186/s12967-025-06425-2 · ExternalCitation · doi-reference

Smoldering myocarditis following immune checkpoint blockade

10.1186/s40425-017-0296-4 · ExternalCitation · doi-reference

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors

10.1186/s40425-019-0535-y · ExternalCitation · doi-reference

Cardiotoxicity risk factors with immune checkpoint inhibitors

10.1186/s40959-022-00130-5 · ExternalCitation · doi-reference

Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance

10.1186/s40959-023-00166-1 · ExternalCitation · doi-reference

Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort

10.1186/s40959-024-00289-z · ExternalCitation · doi-reference

How should immune checkpoint inhibitor myocarditis be treated?

10.1186/s40959-025-00404-8 · ExternalCitation · doi-reference

Immune checkpoint inhibitor-related myocarditis: recognition, surveillance, and management

10.1188/22.cjon.54-60 · ExternalCitation · doi-reference

Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention

10.1200/jco.2017.76.3920 · ExternalCitation · doi-reference

Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase III JAVELIN renal 101 trial

10.1200/jco.21.01806 · ExternalCitation · doi-reference

Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors

10.1371/journal.pone.0314555 · ExternalCitation · doi-reference

Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors

10.14735/amko2020350 · ExternalCitation · doi-reference

Immune checkpoint inhibitor-associated myocarditis

10.1634/theoncologist.2018-0130 · ExternalCitation · doi-reference

Neural net modeling of checkpoint inhibitor related myocarditis and steroid response

10.2147/cpaa.s369008 · ExternalCitation · doi-reference

Cardiovascular toxicities with chimeric antigen receptor T-cell therapy

10.2174/1573403x18666220623152350 · ExternalCitation · doi-reference

Mechanisms and management of immune checkpoint inhibitor-related cardiac adverse events

10.31662/jmaj.2021-0001 · ExternalCitation · doi-reference

Immune checkpoint inhibitor therapy in metastatic renal cell carcinoma: tumour response and immune-related renal vasculitis following cytoreductive nephrectomy

10.32074/1591-951x-n998 · ExternalCitation · doi-reference

Early detection of checkpoint inhibitor-associated myocarditis using (68)Ga-FAPI PET/CT

10.3389/fcvm.2021.614997 · ExternalCitation · doi-reference

Immune checkpoint inhibitors mediated lymphocytic and giant cell myocarditis: uncovering etiological mechanisms

10.3389/fcvm.2021.721333 · ExternalCitation · doi-reference

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors

10.3389/fcvm.2022.1062858 · ExternalCitation · doi-reference

Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: a single-center experience

10.3389/fcvm.2023.1093383 · ExternalCitation · doi-reference

Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology

10.3389/fcvm.2024.1232269 · ExternalCitation · doi-reference

Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach

10.3389/fcvm.2024.1350585 · ExternalCitation · doi-reference

Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity

10.3389/fcvm.2024.1408586 · ExternalCitation · doi-reference

Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors

10.3389/fimmu.2022.779691 · ExternalCitation · doi-reference

TNF-α Inhibitors and other biologic agents for the treatment of immune checkpoint inhibitor-induced myocarditis

10.3389/fimmu.2022.922782 · ExternalCitation · doi-reference

Advances in immune checkpoint inhibitors induced-cardiotoxicity

10.3389/fimmu.2023.1130438 · ExternalCitation · doi-reference

Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

10.3389/fimmu.2024.1340373 · ExternalCitation · doi-reference

The impact of immune checkpoint inhibition on atherosclerosis in cancer patients

10.3389/fimmu.2025.1604989 · ExternalCitation · doi-reference

Role of cardiac imaging in the diagnosis of immune checkpoints inhibitors related myocarditis

10.3389/fonc.2021.640985 · ExternalCitation · doi-reference

Immunotherapy-associated cardiovascular toxicities: insights from preclinical and clinical studies

10.3389/fonc.2024.1347140 · ExternalCitation · doi-reference

How to monitor cardiac complications of immune checkpoint inhibitor therapy

10.3389/fphar.2020.00972 · ExternalCitation · doi-reference

Immune checkpoint inhibitor-related myositis overlapping with myocarditis: an institutional case series and a systematic review of literature

10.3389/fphar.2022.884776 · ExternalCitation · doi-reference

Immunotherapy-related cardiovascular toxicity: from mechanisms to management

10.3389/fphar.2026.1762011 · ExternalCitation · doi-reference

Immunopathogenesis of immune checkpoint inhibitor induced myocarditis: insights from experimental models and treatment implications

10.3390/biomedicines11010107 · ExternalCitation · doi-reference

Role of cardiac biomarkers in cancer patients

10.3390/cancers13215426 · ExternalCitation · doi-reference

Pathophysiology of immune checkpoint inhibitor-induced myocarditis

10.3390/cancers14184494 · ExternalCitation · doi-reference

Cardiotoxicity induced by immune checkpoint inhibitors: what a cardio-oncology team should know and do

10.3390/cancers14215403 · ExternalCitation · doi-reference

Takotsubo cardiomyopathy in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-summary of included cases

10.3390/cancers15092637 · ExternalCitation · doi-reference

In the era of cardiovascular-kidney-metabolic syndrome in cardio-oncology: from pathogenesis to prevention and therapy

10.3390/cancers17071169 · ExternalCitation · doi-reference

Artificial intelligence and the expanding universe of cardio-oncology: beyond detection toward prediction and prevention of therapy-related cardiotoxicity—a comprehensive review

10.3390/diagnostics16030488 · ExternalCitation · doi-reference

Elevated IL-6 and tumor necrosis factor-α in immune checkpoint inhibitor myocarditis

10.3390/diseases12050088 · ExternalCitation · doi-reference

Cardiotoxicity of chimeric antigen receptor T-cell (CAR-T) therapy: pathophysiology, clinical implications, and echocardiographic assessment

10.3390/ijms23158242 · ExternalCitation · doi-reference

Navigating cardiotoxicity in immune checkpoint inhibitors: from diagnosis to long-term management

10.3390/jcdd12070270 · ExternalCitation · doi-reference

The potential cardiotoxicity of immune checkpoint inhibitors

10.3390/jcm11030865 · ExternalCitation · doi-reference

Immune checkpoint inhibitors-associated myocarditis: diagnosis, treatment and current Status on rechallenge

10.3390/jcm12247737 · ExternalCitation · doi-reference

Multimodal imaging of immune checkpoint inhibitor myocarditis

10.3390/jcm14082850 · ExternalCitation · doi-reference

Immune checkpoint inhibitor-associated myocarditis: risk, diagnosis, and clinical impact

10.3390/jcm15020814 · ExternalCitation · doi-reference

Perimyocarditis associated with immune checkpoint inhibitors: a case report and review of the literature

10.3390/medicina60020224 · ExternalCitation · doi-reference

Extensive CArdioVAscular characterization and follow-up of patients receiving immune checkpoint inhibitors: a prospective multicenter study

10.3390/ph16040625 · ExternalCitation · doi-reference

Prognostic value of troponin to lymphocyte ratio in patients with immune checkpoint inhibitor-associated myocarditis

10.36660/abc.20250047i · ExternalCitation · doi-reference

Risk factors and diagnostic biomarkers for asymptomatic immune checkpoint inhibitor-related myocarditis in patients with esophageal cancer after immunotherapy

10.3748/wjg.v31.i26.106509 · ExternalCitation · doi-reference

Cardiac toxicities associated with immune checkpoints inhibitors: mechanisms, manifestations and management

10.4070/kcj.2021.0089 · ExternalCitation · doi-reference

Durvalumab-Associated myocarditis initially presenting with sinus bradycardia progressing into complete heart block

10.7759/cureus.40171 · ExternalCitation · doi-reference